

2006 (12)

Booy EP, Johar D, Maddika S, Pirzada H, Sahib MM, Gehrke I, Loewen S, Louis SF, Kadkhoda K, Mowat M, Los M. Monoclonal and bispecific antibodies as novel therapeutics. *Archivum immunologiae et therapiae experimentalis*. 2006 54 (2) 85-101

Cool D, Downey D, Izawa J, Chin J, Fenster A. 3D prostate model formation from non-parallel 2D ultrasound biopsy images. *Medical Image Analysis*. 2006 Dec; 10 875-887

El-Alfy M, Azzi L, Lessard J, Lavergne E, Pelletier M, Labrie C. Stage-Specific Expression of the Atce1/Tisp40 α Isoform of CREB3L4 in Mouse Spermatids. *Journal of Andrology*. 2006 Sept-Oct; 27 (5) 686-694

Fan C, Quan R, Feng X, Gillis A, He L, Matsumoto ED, Salama S, Cutz JC, Kapoor A, Tang D. ATM activation is accompanied with earlier stages of prostate tumorigenesis. *Biochimica et Biophysica acta - Molecular Cell Research*. 2006 Oct; 1763 1090-1097

Guo C, Wu G, Chin JL, Bauman G, Moussa M, Wang F, Greenberg NM, Taylor SS, Xuan JW. Bub1 Up-Regulation and Hyperphosphorylation Promote Malignant Transformation in SV40 Tag-Induced Transgenic Mouse Models. *Molecular Cancer Research*. 2006 Dec; 4 957-969

Johnston JB, Navaratnam S, Pitz MW, Maniate JM, Wiechec E, Baust H, Gingerich J, Skliris GP, Murphy LC, Los M. Targeting the EGFR pathway for cancer therapy. *Current Medicinal Chemistry*. 2006 13 (29) 3483-3492

Krocak Tadeusz J, Baran Jaroslaw, Pryjma Juliusz, Siedlar Maciej, Reshedi Iran, Hernandez Elizabeth, Alberti Esteban, Maddika Subbareddy, Los Marek. The emerging importance of DNA mapping and other comprehensive screening techniques, as tools to identify new drug targets and as a means of (cancer) therapy personalisation. *Expert Opinion on Therapeutic Targets*. 2006 Apr; 10 (2) 289-302

Krzemieniecki K, Szpyt E, Rashedi I, Gawron K, Los M. Targeting of solid tumors and blood malignancies by antibody-based therapies - EGFR-pathway as an example. *Central European Journal of Biology*. 2006 Jun; 1 (2) 167-182

Maddika S, Mendoza FJ, Hauff K, Zamzow CR, Paranjothy T, Los M. Cancer-selective therapy of the future: apoptin and its mechanism of action. *Cancer Biology and Therapy*. 2006 Jan; 5 43739

Shukeir N, Pakneshan P, Chen G, Szyf M, Rabbani SA. Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. *Cancer Research*. 2006 Sep; 66 9202-9210

Silha JV, Sheppard PC, Mishra S, Gui Y, Schwartz J, Dodd JG, Murphy LJ. Insulin-Like Growth Factor (IGF) Binding Protein-3 Attenuates Prostate Tumor Growth by IGF-Dependent and IGF-Independent Mechanisms. *Endocrinology*. 2006 May; 147 2112-2121

Yoshimoto Maisa, Joshua Anthony M, Chilton-Macneill Susan, Bayani Jane, Selvarajah Shamini, Evans

Andrew J, Zielenska Maria, Squire Jeremy A. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. *Neoplasia*. 2006 Jun; 8 465-469